Gemin X Adds $16 Million

Gemin X Pharmaceuticals Inc., an oncology drug developer with offices in both Malvern, Pa. and Montreal, has raised $16 million in Series D funding. The deal also includes an investor option to invest an additional $4 million. Return backers Caxton Advantage Life Sciences Fund and Sanderling Venture Partners co-led the round. The company has now raised over $100 million, from Caxton, Sanderling, H.I.G. Ventures, CDP/Vantage Point, ProQuest, Merlin BioMed Group, HBM Partners, Canadian Medical Discoveries Fund, Ontario Teachers' Pension Plan Board, SoftBank Life Science, Business Development Bank of Canada, Solidarity Fund QFL and Pinnacle Bioventures.

North AmericaUSBriefs